← All trials
NCT07241520
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Jun 30, 2027
- Completion date
- Nov 30, 2027
- First posted
- Nov 21, 2025
- Last posted
- Nov 21, 2025
- Enrollment
- 1096
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Hutchison Pharmaceuticals LimitedLead sponsor
- Capital Medical UniversityCollaborator
- Capital Medical UniversityOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.